Eli Lilly Shares Gain After Novo Nordisk’s Obesity Drug Falls Short in Head-to-Head Trial
Eli Lilly premarket shares rose after Novo Nordisk reported its experimental obesity drug CagriSema did not meet the trial's primary endpoint of non-inferiority to Eli Lilly's Tirzepatide. The trial showed a 23% weight reduction for CagriSema versus 25.5% for Tirzepatide over 84 weeks. Novo Nordisk will test a higher dose in the second half of 2026…